Transplantation of CD34+ selected peripheral blood to HLA-identical sibling patients with aplastic anaemia: Results from a single institution

J. de la Rubia, S. Cantero, G. F. Sanz, M. J. Remigia, E. Monteagudo, F. Moscardó, G. Martín, I. Lorenzo, C. Jiménez, J. Martínez, P. Montesinos, I. Jarque, M. A. Sanz

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

We evaluated the use of CD34+ selected allogeneic peripheral blood as a source of hematopoietic progenitors for allogeneic transplantation in 11 patients with aplastic anemia (AA). The median age was 17 years (range, 6-49), and the median time between diagnosis and transplant 1 month (range, 1-24). Conditioning consisted of cyclophosphamide (50mg/kg per day) on days -7 to -4 and antithymocyte globulin (30 mg/kg per day) on days -4 to -2 in nine patients. Total lymphoid irradiation was added to the preparative regimen for two. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine A and prednisone. Median doses of CD34 + and CD3 + cells infused were 3.91 × 106 and 0.3 × 106 /kg, respectively. The median time taken to achieve a neutrophil count > 0.5 × 109/l was 12 days and to recover a platelet count > 20 × 1069/l, 13 days. Two patients developed acute GVHD grade I-II and one developed limited chronic GVHD. There were two treatment-related deaths. At a median follow-up of 44 months (range, 4-73), nine patients were alive with sustained and complete engraftment. This is a promising procedure in patients with AA, resulting in a rapid hematopoietic recovery, a low transplant-related mortality, and a low incidence of GVHD.

Original languageEnglish (US)
Pages (from-to)325-329
Number of pages5
JournalBone Marrow Transplantation
Volume36
Issue number4
DOIs
StatePublished - Aug 2005

Keywords

  • Allogeneic transplantation
  • Aplastic anemia
  • CD34+ selection
  • Peripheral blood

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Transplantation of CD34+ selected peripheral blood to HLA-identical sibling patients with aplastic anaemia: Results from a single institution'. Together they form a unique fingerprint.

Cite this